Clinical Safety

Tampa General Gets C Grade in Hospital Safety; Other FL Hospitals Excel
Research & Development Tampa General Gets C Grade in Hospital Safety; Other FL Hospitals Excel

The recent hospital safety ratings in Florida have sparked significant discussion, especially with Tampa General Hospital receiving a C grade from Leapfrog, an independent nonprofit that rates hospital safety. This rating marks the fifth time in the last six Leapfrog assessments that the hospital

How Will NIH Grant Help Fight Multidrug-Resistant Bacterial Infections?
Research & Development How Will NIH Grant Help Fight Multidrug-Resistant Bacterial Infections?

Imagine facing a post-antibiotic era where previously manageable infections become deadly due to rampant multidrug-resistant bacteria. This emerging threat to global health has pushed scientists to innovate to avert a crisis. The National Institutes of Health (NIH) has awarded $3.96 million to

Nurse Burnout Threatens Patient Safety and Satisfaction, Study Finds
Research & Development Nurse Burnout Threatens Patient Safety and Satisfaction, Study Finds

In today's healthcare landscape, the issue of nurse burnout has become an increasingly pressing concern, not only for the well-being of healthcare providers but also for the safety and satisfaction of patients. With the intensity of their workload heightened by the COVID-19 pandemic, an

Vertex's Suzetrigine Shows Promise as a Non-Opioid Painkiller
Research & Development Vertex's Suzetrigine Shows Promise as a Non-Opioid Painkiller

Vertex Pharmaceuticals is on the brink of introducing suzetrigine, a cutting-edge non-opioid painkiller that has showcased promising results in recent phase 3 clinical trials. As the battle against opioid addiction and abuse intensifies, the advent of suzetrigine brings hope for a safer approach to

Will BNT326/YL202 Overcome Safety Issues to Become a Cancer Therapy?
Research & Development Will BNT326/YL202 Overcome Safety Issues to Become a Cancer Therapy?

The journey of developing groundbreaking cancer therapies is fraught with challenges and triumphs, and the clinical trial of BNT326/YL202 by BioNTech and MediLink Therapeutics is no exception. This antibody-drug conjugate (ADC) candidate has shown promise in treating non-small cell lung cancer and

FDA Lifts Hold on BioNTech and MediLink’s Cancer Drug Trial
Research & Development FDA Lifts Hold on BioNTech and MediLink’s Cancer Drug Trial

In an impressive turn of events, the U.S. Food and Drug Administration (FDA) has lifted the partial hold on BioNTech and MediLink Therapeutics' clinical trial for their groundbreaking Antibody-Drug Conjugate (ADC) candidate BNT326/YL202. Originally put on hold due to serious safety concerns,

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later